BioCardia and StemCardia announced a long-term partnership to advance StemCardia’s investigational pluripotent stem cell product candidate for the treatment of heart failure. Under the partnership, BioCardia is the exclusive biotherapeutic delivery partner for StemCardia’s cell therapy candidate through studies expected to result in FDA approval of an investigational new drug application and the anticipated Phase I/II clinical development to follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BCDA:
- BioCardia Partners with StemCardia for Heart Therapy Trials
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
- BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
- Biotech Alert: Searches spiking for these stocks today
- BioCardia Reports Promising Phase III CardiAMP Trial Results
